## David Katzenstein

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6507820/david-katzenstein-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 121
 4,816
 40
 66

 papers
 citations
 h-index
 g-index

 127
 5,229
 6
 4.69

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
121	Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245085	3.7	O
120	Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 748-750	1.6	4
119	Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 776-783	1.6	1
118	Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 181-185	3.1	0
117	Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA). <i>Pan African Medical Journal</i> , <b>2021</b> , 40, 57	1.2	O
116	Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	4
115	Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 566-573	1.6	8
114	Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe. <i>BMC Womenis Health</i> , <b>2020</b> , 20, 153	2.9	1
113	Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 96, 276-283	10.5	1
112	Community-based self-collected human papillomavirus screening in rural Zimbabwe. <i>BMC Public Health</i> , <b>2019</b> , 19, 603	4.1	8
111	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , <b>2019</b> , 9, 26-34	11.3	29
110	Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy. <i>Aids</i> , <b>2019</b> , 33, 1729-1737	3.5	8
109	Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe. <i>International Journal of Infectious Diseases</i> , <b>2019</b> , 78, 65-71	10.5	6
108	HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy005	1	18
107	Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 2799	5.7	5
106	A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 2172-2179	9.7	8
105	Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency</i> Syndromes (1999), <b>2017</b> , 76, 55-59	3.1	20

## (2013-2017)

104	HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing. <i>Journal of Virological Methods</i> , <b>2017</b> , 243, 151-157	2.6	4
103	Community Based Antiretroviral Treatment in Rural Zimbabwe. <i>AIDS Research and Human Retroviruses</i> , <b>2017</b> , 33, 1185-1191	1.6	7
102	Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic. <i>Journal of AIDS and HIV Research (Online)</i> , <b>2017</b> , 9, 17-30	0.4	6
101	Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 250-6	7	10
100	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 836-843	11.6	28
99	Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw154	1	1
98	Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001810	11.6	163
97	Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 960-71	5.9	40
96	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , <b>2015</b> , 528, S68-76	50.4	118
95	HIV drug resistance mutations in proviral DNA from a community treatment program. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117430	3.7	28
94	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145772	3.7	58
93	Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 555-63	11.6	28
92	An affordable HIV-1 drug resistance monitoring method for resource limited settings. <i>Journal of Visualized Experiments</i> , <b>2014</b> ,	1.6	24
91	HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077. <i>PLoS ONE</i> , <b>2014</b> , 9, e93537	3.7	9
90	HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19262	5.4	12
89	Drug susceptibility and resistance mutations after first-line failure in resource limited settings. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 706-15	11.6	29
88	Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe. <i>Current HIV Research</i> , <b>2014</b> , 12, 309-16	1.3	5
87	Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clinical Trials, 2013, 14, 284-91	_	4

86	Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207 Suppl 2, S70-7	7	28
85	Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa. <i>Journal of the International AIDS Society</i> , <b>2013</b> , 16, 18580	5.4	8
84	HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2012</b> , 24, 358-68	2.2	42
83	Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 995-1000	11.6	25
82	HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1920-	·3 <del>7</del> 0	16
81	Primary drug resistance in South Africa: data from 10 years of surveys. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 558-65	1.6	45
80	Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, e26-7	3.1	
79	Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. <i>PLoS ONE</i> , <b>2012</b> , 7, e31558	3.7	10
78	The point of point-of-care testing. Lancet, The, 2011, 378, 1532-3	40	2
77	Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis. <i>HIV Clinical Trials</i> , <b>2011</b> , 12, 79-88		6
76	Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 445-56	8	236
75	Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. <i>BMC Public Health</i> , <b>2011</b> , 11, 88	4.1	58
74	Placental malaria and mother-to-child transmission of human immunodeficiency virus-1 in rural Rwanda. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2011</b> , 85, 202-6	3.2	17
73	Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1191-201	7	133
72	Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. <i>PLoS ONE</i> , <b>2011</b> , 6, e17518	3.7	73
71	Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. <i>PLoS ONE</i> , <b>2011</b> , 6, e21241	3.7	10
70	Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. <i>Journal of AIDS &amp; Clinical Research</i> , <b>2011</b> , 2,	1	21
69	The Incidence and Correlates of Symptomatic and Asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Selected Populations in Five Countries. <i>Sexually Transmitted Diseases</i> , <b>2011</b> , 38, 503-509	2.4	107

## (2007-2010)

68	Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. <i>Aids</i> , <b>2010</b> , 24, 1679-87	3.5	86
67	Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5). <i>Aids</i> , <b>2010</b> , 24, 1063-4	3.5	3
66	Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. <i>PLoS ONE</i> , <b>2010</b> , 5, e10992	3.7	51
65	Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe. <i>African Journal of Reproductive Health</i> , <b>2010</b> , 14, 27-35	0.8	19
64	CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. <i>Journal of Virology</i> , <b>2009</b> , 83, 5592-605	6.6	76
63	Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. <i>Aids</i> , <b>2009</b> , 23, 2523-32	3.5	39
62	Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2009</b> , 50, 9-18	3.1	15
61	Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2009</b> , 21, 1517-27	2.2	40
60	Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1601-8	11.6	17
59	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. <i>Journal of Virological Methods</i> , <b>2009</b> , 159, 185-93	2.6	31
58	Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. <i>Journal of Virological Methods</i> , <b>2009</b> , 159, 211-6	2.6	38
57	Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2230-40	59.2	241
56	Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 1005-9	1.6	23
55	Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 685-94	1.6	23
54	Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. <i>PLoS ONE</i> , <b>2008</b> , 3, e2021	3.7	46
53	Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. <i>HIV Clinical Trials</i> , <b>2007</b> , 8, 63-7		2
52	Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 1055-61	1.6	25
51	Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs. <i>Journal of Immigrant and Minority Health</i> , <b>2007</b> , 9, 49-54	2.2	61

50	Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194 Suppl 1, S45-50	7	13
49	Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe. <i>International Journal of STD and AIDS</i> , <b>2006</b> , 17, 835-41	1.4	11
48	Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 694-701	5.9	71
47	A pilot study evaluating time to CD4 T-cell count . <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2006</b> , 42, 140-8	3.1	29
46	Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 285-91	1.6	24
45	Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 252-4	11.6	2
44	HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 301-5	1.6	57
43	Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1176-84	7	71
42	Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. <i>Journal of Virology</i> , <b>2004</b> , 78, 3233-43	6.6	193
41	Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 886-93	7	24
40	Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. <i>Aids</i> , <b>2004</b> , 18, 1503-11	3.5	82
39	The longer the better? Four years of durable, initially boosted protease treatment. <i>Aids</i> , <b>2004</b> , 18, 811-	3 3.5	
38	Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. <i>Journal of Immunology</i> , <b>2004</b> , 173, 4607-17	5.3	47
37	Drug resistance in non-subtype B HIV-1. <i>Journal of Clinical Virology</i> , <b>2004</b> , 29, 152-9	14.5	76
36	Assessing resistance costs of antiretroviral therapies via measures of future drug options. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1001-8	7	27
35	The evaluation of the HIV/AIDS Drug Access Initiatives in CEe DEvoire, Senegal and Uganda. <i>Aids</i> , <b>2003</b> , 17, S1-S4	3.5	27
34	Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. <i>AIDS Reviews</i> , <b>2003</b> , 5, 25-35	1.5	70
33	Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 626-33	7	10

32	Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe. <i>HIV Clinical Trials</i> , <b>2002</b> , 3, 148-54		3
31	A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. <i>Aids</i> , <b>2002</b> , 16, 1147-54	3.5	24
30	Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. <i>Aids</i> , <b>2001</b> , 15, 1125-32	3.5	59
29	Plasma carnitine in HIV-associated neuropathy. <i>Aids</i> , <b>2001</b> , 15, 2207-8	3.5	16
28	Prenatal Transmission of Subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in Maternal and Cord Blood. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2000</b> , 25, 390-397	3.1	5
27	Vertical transmission of HIV in Africa: diagnostic testing and new interventions. <i>HIV Clinical Trials</i> , <b>2000</b> , 1, 51-7		
26	Correlates of HIV Test Results Seeking and Utilization of Partner Counseling Services in a Cohort of Male Factory Workers in Zimbabwe. <i>AIDS and Behavior</i> , <b>2000</b> , 4, 63-70	4.3	12
25	Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. <i>Aids</i> , <b>2000</b> , 14, 2495-501	3.5	33
24	Detection of Kaposiß sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1785-90	7	43
23	Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 1375-84	7	79
22	The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan. <i>Antiviral Therapy</i> , <b>2000</b> , 5, 41-48	1.6	160
21	Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1999</b> , 20, 455-62		12
20	Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 180, 1459-65	7	92
19	HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 813-21	8	163
18	Sexual behaviour and risk assessment of HIV seroconvertors among urban male factory workers in Zimbabwe. <i>Social Science and Medicine</i> , <b>1998</b> , 47, 1431-43	5.1	18
17	Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 109-13	7	91
16	Human immunodeficiency virus type 1 RNA shedding in the female genital tract. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 1100-3	7	54
15	Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. <i>AIDS Research and Human Retroviruses</i> , <b>1998</b> , 14, 533-6	1.6	47

14	Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 481-4	7	73
13	Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. <i>Aids</i> , <b>1998</b> , 12, 2295-303	3.5	90
12	The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. <i>Aids</i> , <b>1998</b> , 12, 2305-11	3.5	45
11	Human immunodeficiency virus type 1 populations in blood and semen. <i>Journal of Virology</i> , <b>1998</b> , 72, 617-23	6.6	141
10	Combination therapies for HIV infection and genomic drug resistance. <i>Lancet, The</i> , <b>1997</b> , 350, 970-1	40	15
9	An evaluation of dipstick-dot immunoassay in the detection of antibodies to HIV-1 and 2 in Zimbabwe. <i>Tropical Medicine and International Health</i> , <b>1997</b> , 2, 83-8	2.3	32
8	Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 15, 269-74		14
7	Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. <i>Journal of Infectious Diseases</i> , <b>1996</b> , 174, 854-7	7	21
6	HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. <i>Aids</i> , <b>1996</b> , 10, 895-901	3.5	67
5	Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1995</b> , 10, 150-6		4
4	Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 170, 1044-6	7	4
3	Isolated Candida arthritis: report of a case and definition of a distinct clinical syndrome. <i>Arthritis and Rheumatism</i> , <b>1985</b> , 28, 1421-4		36
2	New concepts of amebic liver abscess derived from hepatic imaging, serodiagnosis, and hepatic enzymes in 67 consecutive cases in San Diego. <i>Medicine (United States)</i> , <b>1982</b> , 61, 237-46	1.8	104
1	Botulism, type A, and treatment with guanidine. <i>Annals of Neurology</i> , <b>1979</b> , 6, 69-71	9.4	31